Brain-immune crosstalk in the treatment of major depressive disorder

the European College of Neuropsychopharmacology (ECNP) ImmunoNeuroPsychiatry Thematic Working Group and Marion Leboyer

Research output: Contribution to journalArticleAcademicpeer-review

34 Citations (Scopus)
76 Downloads (Pure)


A growing number of studies are pointing out the need for a conceptual shift from a brain-centered to a body-inclusive approach in mental health research. In this perspective, the link between the immune and the nervous system, which are deeply interconnected and continuously interacting, is one of the most important novel theoretical framework to investigate the biological bases of major depressive disorder and, more in general, mental illness. Indeed, depressed patients show high levels of inflammatory markers, administration of pro-inflammatory drugs triggers a depressive symptomatology and antidepressant efficacy is reduced by excessive immune system activation. A number of molecular and cellular mechanisms have been hypothesized to act as a link between the immune and brain function, thus representing potential pharmacologically targetable processes for the development of novel and effective therapeutic strategies. These include the modulation of the kynurenine pathway, the crosstalk between metabolic and inflammatory processes, the imbalance in acquired immune responses, in particular T cell responses, and the interplay between neural plasticity and immune system activation. In the personalized medicine approach, the assessment and regulation of these processes have the potential to lead, respectively, to novel diagnostic approaches for the prediction of treatment outcome according to the patient's immunological profile, and to improved efficacy of antidepressant compounds through immune modulation.

Original languageEnglish
Pages (from-to)89-107
Number of pages19
JournalEuropean Neuropsychopharmacology
Publication statusPublished - Apr 2021

Bibliographical note

Funding Information:
Supported by ERANET Neuron 2017 MicroSynDep and ERANET Neuron 2018 ADORe, both to IB. ML, FB and HAD are funded by the EU 7th Framework program (MOODINFLAME; EU-FP7-CP-IP-2008-222963) and Horizon 2020 (MOODSTRATIFICATION; H2020-SC1-2016-2017/H2020-SC1-2017-Two-Stage-RTD).

Funding Information:
BP has received (non-related) research funding from Boehringer Ingelheim and Jansen Research. CMP is funded by the National Institute for Health Research (NIHR) Biomedical Research Center at South London and Maudsley NHS Foundation Trust and King's College London, and is a NIHR Senior Investigator; moreover, he has received research funding from Johnson & Johnson for research on depression and inflammation, and by the Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer's Disease (NIMA) Consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck and Pfizer, but this paper is independent from this funding.

Publisher Copyright:
© 2020 Elsevier B.V. and ECNP


Dive into the research topics of 'Brain-immune crosstalk in the treatment of major depressive disorder'. Together they form a unique fingerprint.

Cite this